We are Innosens

Strategic Pricing & Reimbursement Consultancy for all Health Care Interventions in the Benelux

Learn what we can do

How can we get access for our products in Luxembourg?

Is our health economic model in line with the Belgian recommendations?

How to create a budget impact analysis to support our Belgian Price and reimbursement dossier? How to collect Belgian data for this budget impact analysis?

What managed entry agreement (MEA)/ price could be negotiated for our drug/medical device in Belgium?

Will our product end up in the same added value class after the legislative amendments for pricing & reimbursement in Belgium?

How do we collect the missing data for our Belgian reimbursement dossier?

What are the key factors determining the reimbursement for our medical device in Belgium?

How can we optimize the structure of our pricing & reimbursement dossier?

What are the most important rules to know about the complex market access legal system in Belgium?

How will our pricing & reimbursement application be interpreted by the NIHDI/RIZIV?

Why do we need to pay certain taxes for our product to the Belgian government (NIHDI/FAMHP)?

We need help with our systematic literature review

What are the key factors determining the reimbursement for our drug in Belgium?

Is there an opportunity for an early access program to medicines in Belgium?

How to write the pricing & reimbursement dossier? We need support with submission of our pricing & reimbursement dossier in Belgium.

What is the optimal path for reimbursement?

How can the new legislation be translated to a pragmatic approach?

Does our health economic model meet the methodological Belgian recommendations? and how to implement our health economic model in the Belgian context?

How will the new reimbursement chapter and companioning legislative amendments about personalized medicines and their markers affect the reimbursement of our product?

daisies

Try our market access as a service

Innosens provides advanced services based on market access consulting on the Belgian pharmaceutical market. In the pharmaceutical industry, both technical and emotional aspects affect the strategy of a pharmaceutical company. Innosens likes to combine both aspects to provide a high quality pharmaceutical market access consulting service.

Early Access Program as a service

An early access program to medicines in Belgium is useful when a specific drug is not yet available to one or more patients who suffer from a chronic or serious illness and cannot be satisfactorily treated via any existing health care pathways.

waterfall girl

staircase

Managed Entry Agreements (MEA)

A Managed Entry Agreement (MEA) is a confidential arrangement between a manufacturer and payer/provider that enables access to (coverage/reimbursement of) a health technology subject to specified conditions.

BeNeLuxA(Ir) as a service

BeNeLuxA(Ir) is a joint negotiation procedure for timely and affordable access to very specific innovative drugs in Belgium, The Netherlands, Luxembourg, Austria and Ireland. This can be applied with complex and rare (innovative) medicines, with a higher cost per patient and a relatively high budget impact.

cliff